期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 95, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2021.107518
关键词
Type 1 diabetes; LADA; Vitamin D; DPP-4 inhibitors; Immunomodulation; Immunotherapy; VIDPP-4i
Current research suggests that combination therapy with vitamin D and DPP-4 inhibitors may play a potential role in preserving beta-cell function in autoimmune diabetes. The aim of these therapies is to counteract autoimmune responses and slow down the progression of diabetes.
Type 1 diabetes (T1D) and latent autoimmune diabetes in adults (LADA) represent the most common types of autoimmune diabetes and are characterized by different age of onset, degrees of immune-mediated destruction of pancreatic beta cells and rates of disease progression towards insulin dependence. Several immunotherapies aimed to counteract autoimmune responses against beta cells and preserve beta-cell function are currently being investigated, particularly in T1D. Preliminary findings suggest a potential role of combination therapy with vitamin D and dipeptidyl peptidase-4 (DPP-4) inhibitors (VIDPP-4i) in preserving beta-cell function in autoimmune diabetes. This manuscript aims to provide a comprehensive overview of the immunomodulatory properties of vitamin D and DPP-4 inhibitors, as well as the rationale for investigation of their combined use as an immunomodulation therapy for autoimmune diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据